Activation of c-fos in the brain

doi:10.1016/S0301-0082(96)00021-4

Progress in Neurobiology

Volume 50, Issues 2–3, October 1996, Pages 83-107

https://doi.org/10.1016/S0301-0082(96)00021-4 Get rights and content

Abstract

Activation of the proto-oncogene c-fos in the brain was described initially almost a decade ago and represents one of the most studied immediate early genes in the brain. Transient c-fos expression in the central nervous system was first observed after seizure activity and following noxious stimulation in the spinal cord. Since then, multiple studies have shown that different stimuli can induce c-fos expression. Seizure activity induces rapid and transient expression of c-fos in hippocampal structures. Similarly, transient activation of c-fos follows cortical brain injury in a pattern that resembles that of spreading depression. Many other stimuli have been shown to induce the expression of this proto-oncogene in the brain and c-fos fos immunostaining and in situ hybridization are now used to map brain metabolism under different physiological and non-physiological conditions. Here we review the variety of inducible patterns of c-fos expression in the brain.

References (264)

C. Abbadie et al.
Intense cold noxious stimulation of the rat hindpaw induces c-fos expression in lumbar spinal cord neurons
Neuroscience
(1994)
C. Abbadie et al.
c-fos expression in rat lumbar spinal cord during the development of adjuvant-induced arthritis
Neuroscience
(1992)
H. Abe et al.
Stimulation of the hamster ventral lateral geniculate nucleus induces Fos-like immunoreactivity in suprachiasmatic nucleus cells
Neurosci. Lett.
(1992)
H. Abe et al.
Photic induction of Fos protein in the suprachiasmatic nucleus is inhibited by the NMDA receptor antagonist MK-801
Neurosci. Lett.
(1991)
H. Abe et al.
NMDA and non-NMDA receptor antagonists inhibit photic induction of Fos protein in the hamster suprachiasmatic nucleus
Brain Res. Bull.
(1992)
S. Amir et al.
Induction of Fos protein in the piriform cortex after brain injury in pentobarbitalanaesthetized rats; lack of effect of lactation
Brain Res.
(1994)
A.J. Anderson et al.
Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: association with pathology
Expl Neurol.
(1994)
K.V. Anokhin et al.
Effects of early experience on c-fos gene expression in the chick forebrain
Brain Res.
(1991)
F. Anton et al.
c-fos-like immunoreactivity in rat brainstem neurons following noxious chemical stimulation of the nasal mucosa
Neuroscience
(1991)
N. Aronin et al.
N-methyl-d-aspartate receptor activation in the neostriatum increases c-fos and fos-related antigens selectively in medium-sized neurons
Neuroscience
(1991)

F.I. Arnold et al.

Expression of c-fos in regions of the basal limbic forebrain following intracerebroventricular corticotropin-releasing factor in unstressed or stressed male rats

Neuroscience

(1992)

S. Bele et al.

Concurrent immediate early gene induction by epileptic seizures in heterotopic cortical grafts and neocortex

Brain Res. Mot. Brain Res.

(1994)

G. Bing et al.

Immunohistochemical studies of noradrenergic-induced expression of c-fos in the rat CNS

Brain Res.

(1992)

G.Y. Bing et al.

Noradrenergic activation of immediate early genes in rat cerebral cortex

Brain Res. Mot. Brain Res.

(1991)

E. Bullitt et al.

The effect of stimulus duration on noxious-stimulus induced c-fos expression in the rodent spinal cord

Brain Res.

(1992)

S. Campeau et al.

Induction of the c-fos proto-oncogene in rat amygdala during unconditioned and conditioned fear

Brain Res.

(1991)

D.A. Carter

Differential intracellular mechanisms mediate the co-ordinate induction of c-fos and Jun-B in the rat pineal gland

Eur. J. Pharmacol: Mol. Pharmacol. Sect.

(1993)

S.L. Chang et al.

Morphine activation of c-fos expression in rat brain

Biochem. Biophys. Res. Commun.

(1988)

N. Chastrette et al.

Effects of daytime and nighttime stress on Fos-like immunoreactivity in the paraventricular nucleus of the hypothalamus, the habenula, and the posterior paraventricular nucleus of the thalamus

Brain Res.

(1991)

S. Chen et al.

Transient c-fos expression and dendritic spine plasticity in hippocampal granule cells

Brain Res.

(1992)

B.J. Chiasson et al.

Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain

Eur. J. Pharmacol.

(1992)

M. Clark et al.

Regional expression of c-fos mRNA in rat brain during the evolution of amygdala kindled seizures

Brain Res. Mol. Brain Res.

(1991)

C.S. Colwell et al.

Photic induction of Fos in the hamster suprachiasmatic nucleus is inhibited by baclofen but not by diazepam or bicucullin

Neurosci. Lett.

(1993)

R. Covenas et al.

Coexistence of c-fos and glucocorticoid receptor immunoreactivities in the CRF immunoreactive neurons of the paraventricular hypothalamic nucleus of the rat after acute immobilization stress

Neurosci. Lett.

(1993)

J.A. De Leo et al.

Differential c-Fos-like protein expression in mechanically versus chemically induced visceral nociception

Brain Res. Mot. Brain Res.

(1991)

M. Didier et al.

Cerebellar granule cell survival and maturation induced by K⁺ and NMDA correlate with c-fos proto-oncogene expression

Neurosci. Lett.

(1989)

J.M. Ding et al.

Proto-oncogene c fo:c and the regulation of vasopressin gene expression during dehydration

Brain Res. Mol. Brain Res.

(1994)

R. Douglas et al.

High frequency discharge of dentate granule cells, but not long-term potentiation, induces c-fos protein

Mol. Brain Res.

(1988)

M. Dragunow et al.

Presence of c-fos like i mmunoreactivity in the adult rat brain

Eur. J. Pharmacol.

(1987)

M. Dragunow et al.

Amygdala kindling and c-Fos protein(s)

Expl Neurol.

(1988)

M. Dragunow et al.

Long-term potentiation and the induction of c-fos mRNA and proteins in the dentate gyros of unan.sthetized rats

Neurosci. Lett.

(1989)

M. Dragunow et al.

Heat shock induces c-Fos protein-like immunoreactivity in glial cells in adult rat brain

Expl Neurol.

(1989)

M. Dragunow et al.

Induction of Fos in glia-like cells after local brain injury but not during Wallerian degeneration

Brain Res.

(1990)

M. Dragunow et al.

MK-801, an antagonist of NMDA receptors, inhibits injury-induced c-Fos protein accumulation in rat brain

Neurosci. Lett.

(1990)

M. Dragunow et al.

Induction of c-fos mRNA and protein in neurons and glia after traumatic brain injury: pharmacological characterization

Expl Neurol.

(1990)

M. Dragunow et al.

D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons

Neuroscience

(1990)

M. Dragunow et al.

Haloperidol induces Fos and related molecules in intrastriatal grafts derived from fetal striatal primordia

Brain Res.

(1990)

M. Dragunow et al.

Elevated expression of Jun- and Fos-related proteins in transplanted striatial neurons

Brain Res.

(1991)

M. Dragunow et al.

Prolonged and selective induction of Fos-related antigen(s) in striatal neurons after 6-hydroxydopamine lesions of the rat substantia nigra pars compacta

Brain Res. Mol. Brain Res.

(1991)

M. Dragunow

Axotomized medial septal-diagonal band neurons express Jun-like immunoreactivity

Brain Res. Mol. Brain Res.

(1992)

M. Dragunow et al.

The use of cfos as a metabolic marker in neuronal pathway tracing

J. Neurosci. Meth.

(1989)

M. Dragunow et al.

MK-801 induces c-Fos protein in thalamic and neocortical neurons of rat brain

Neurosci. Lett.

(1990)

M. Dragunow et al.

Generalized seizures induce c-Fos protein(s) in mammalian neurons

Neurosci. Lett.

(1987)

M. Dragunow et al.

Localization and induction of c-Fos protein-like immunoreactive material in the nuclei of adult mammalian neurons

Brain Res.

(1988)

M. Dragunow et al.

Brain injury induces c-Fos protein(s) in nerve and glial-like cells in adult mammalian brain

Brain Res.

(1988)

G. Draisci et al.

Temporal analysis of increases in c-fos, preprodynor~hin and preproenkephalin mRNAs in rat spinal cord

Brain Res. Mol. Brain Res.

(1989)

A. D'Costa et al.

Attenuation offos-like immunoreactivity induced by a single electroconvulsive shock in brains of aging mice

Brain Res.

(1991)

D.J. Earnest et al.

Photic regulation of c-fos expression in neural components governing the entrainment of circadian rhythms

Expl Neurol.

(1990)

D.J. Earnest et al.

Rhythmic expression of Fos-related proteins within the rat suprachiasmatic nucleus during constant retinal illumination

Neurosci. Lett.

(1992)

D.J. Earnest et al.

Light induces expression of Fos-related proteins within gastrin-releasing peptide neurons in the rat suprachiasmatic nucleus

Brain Res.

(1993)

Cited by (594)

Chemogenetic stimulation of intact corticospinal tract during rehabilitative training promotes circuit rewiring and functional recovery after stroke
2024, Experimental Neurology
Neuromodulatory techniques have been proven to enhance functional recovery after stroke in patients and animals, such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS). However, the success and feasibility of these approaches were often variable, largely due to a lack of target specificity.
We explored the effects of specific chemogenetic stimulation of intact corticospinal tract during rehabilitative training on functional recovery after stroke in mice.
We developed a viral-based intersectional targeting approach that allows specific chemogentic activation of contralateral hindlimb corticospinal neurons (CSNs) in a photothrombotic stroke model.
We demonstrated that specific chemogenetic activation of CSNs, when combined with daily rehabilitation training, leads to significant skilled motor functional recovery via promoting corticospinal tract (CST) axons midline crossing sprouting from intact to the denervated spinal hemicord, and rewiring new functional circuits by new synapse formation. Mechanistically, we revealed that combined chemogenetic stimulation of CSNs and daily rehabilitation training significantly enhanced the mTOR activity of CSNs.
Our findings highlight the great potential of specific neural activation protocols in combination with motor training for the recovery of skilled motor functions after stroke.
Verbascoside: A neuroprotective phenylethanoid glycosides with anti-depressive properties
2023, Phytomedicine
Verbascoside is a natural and water-soluble phenylethanoid glycoside found in several medicinal plants. It has extensive pharmacological effects, including antioxidative and antineoplastic actions, and a wide range of therapeutic effects against depression.
In this review, we appraised preclinical and limited clinical evidence to fully discuss the anti-depression capacity of verbascoside and its holistic characteristics that can contribute to better management of depression in vivo and in vitro models, as well as, its toxicities and medicinal value.
This review was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A systematic review of 32 preclinical trials published up to April 2023, combined with a comprehensive bioinformatics analysis of network pharmacology and molecular docking, was conducted to elucidate the antidepressant mechanism of action of verbascoside. Studies included in the systematic review were obtained from 7 electronic databases: PubMed, Scopus, Web of Science, Cochrane, ResearchGate, ScienceDirect, and Google Scholar.
Studies on the antidepressant effects of verbascoside showed that various pharmacological mechanisms and pathways, such as modulating the levels of monoamine neurotransmitters, inhibiting hypothalamic-pituitary-adrenal (HPA) axis hyperfunction and promoting neuroprotection may be involved in the process of its action against depression. Verbascoside promotes dopamine (DA) biosynthesis by promoting the expression of tyrosine hydroxylase mRNA and protein, upregulates the expression of 5-hydroxytryptamine receptor 1B (5-HT1B), prominence protein, microtubule-associated protein 2 (MAP2), hemeoxygenase-1 (HO-1), SQSTM1, Recombinant Autophagy Related Protein 5 (ATG5) and Beclin-1, and decreases the expression of caspase-3 and a-synuclein, thus exerting antidepressant effects. We identified seven targets (CCL2, FOS, GABARAPL1, CA9, TYR, CA12, and SQSTM1) and three signaling pathways (glutathione metabolism, metabolism of xenobiotics by cytochrome P450, fluid shear stress and atherosclerosis) as potential molecular biological sites for verbascoside.
These findings provide strong evidence that verbascoside exerts its antidepressant effects through various pharmacological mechanisms. However, further multicentre clinical case-control and molecularly targeted fishing studies are required to confirm the clinical efficacy of verbascoside and its underlying direct targets.
Elevated susceptibility to exogenous seizure triggers and impaired interneuron excitability in a mouse model of Leigh syndrome epilepsy
2023, Neurobiology of Disease
Mutations in the NADH dehydrogenase (ubiquinone reductase) iron‑sulfur protein 4 (NDUFS4) gene, which encodes for a key structural subunit of the OXFOS complex I (CI), lead to the most common form of mitochondrial disease in children known as Leigh syndrome (LS). As in other mitochondrial diseases, epileptic seizures constitute one of the most significant clinical features of LS. These seizures are often very difficult to treat and are a sign of poor disease prognosis. Mice with whole-body Ndufs4 KO are a well-validated model of LS; they exhibit epilepsy and several other clinical features of LS. We have previously shown that mice with Ndufs4 KO in only GABAergic interneurons (Gad2-Ndufs4-KO) reproduce the severe epilepsy phenotype observed in the global KO mice. This observation indicated that these mice represent an excellent model of LS epilepsy isolated from other clinical manifestations of the disease. To further characterize this epilepsy phenotype, we investigated seizure susceptibility to selected exogenous seizure triggers in Gad2-Ndufs4-KO mice. Then, using electrophysiology, imaging, and immunohistochemistry, we studied the cellular, physiological, and neuroanatomical consequences of Ndufs4 KO in GABAergic interneurons. Homozygous KO of Ndufs4 in GABAergic interneurons leads to a prominent susceptibility to exogenous seizure triggers, impaired interneuron excitability and interneuron loss. Finally, we found that the hippocampus and cortex participate in the generation of seizure activity in Gad2-Ndufs4-KO mice. These findings further define the LS epilepsy phenotype and provide important insights into the cellular mechanisms underlying epilepsy in LS and other mitochondrial diseases.
Tenuigenin promotes non-rapid eye movement sleep via the GABA<inf>A</inf> receptor and exerts somnogenic effect in a MPTP mouse model of Parkinson's disease
2023, Biomedicine and Pharmacotherapy
Sleep disturbances are commonly non-motor symptoms in Parkinson's diseases (PD). However, standard dopamine replacement therapies for the treatment of motor symptoms often prove inadequate in combating sleep disturbances. Previous studies conducted by our research group have reported the neuroprotective effects of tenuigenin, a natural extract from Polygala tenuifolia root, which has been traditionally employed in treating insomnia. The objective of this study was to investigate the potential of tenuigenin in modulating sleep-wake behaviors and elucidate the underlying mechanisms. We employed EEG/EMG recordings to evaluate the impact of tenuigenin on sleep-wake profiles. Furthermore, we utilized c-Fos immunostaining, whole-cell patch clamping and local field potentials (LFP) recording to explore the mechanisms involved in sleep-promoting effects of tenuigenin. Additionally, we examined the effects of tenuigenin on sleep-promoting in MPTP PD mice. Here, we found tenuigenin demonstrated a significant increase in NREM sleep and a reduction in sleep latency in mice, without altering the EEG power density. Moreover, tenuigenin increased c-Fos expression in the ventrolateral preoptic area (VLPO) and stimulated sleep-promoting neurons in VLPO. The sleep-promoting effects of tenuigenin were abolished when mice were pretreated with flumazenil, an antagonist at the benzodiazepine site of the GABA_A receptor. Furthermore, tenuigenin was found to ameliorate sleep disturbances in MPTP-induced mice. The results suggesting that tenuigenin facilitated a type of NREM sleep comparable to physiological NREM sleep through interaction with the GABA_A receptor. Additionally, tenuigenin demonstrated improvements in sleep disturbances in MPTP-induced PD mice, suggesting its potential as a sleep-promoting substance, particularly for PD patients experiencing sleep disturbances.
Trigeminal nerve stimulation restores hippocampal dopamine deficiency to promote cognitive recovery in traumatic brain injury
2023, Progress in Neurobiology
Cognitive impairment (CI) is a common neurological disease resulting from traumatic brain injury (TBI). Trigeminal nerve stimulation (TNS) is an emerging, non-invasive, and effective neuromodulation therapy especially for patients suffering from brain function disorders. However, the treatment and recovery mechanisms of TNS remain poorly understood. By using combined advanced technologies, we revealed here that the neuroprotective potential of TNS to improve CI caused by TBI. The study results found that 40 Hz TNS treatment has the ability to improve CI in TBI mice and communicates with central nervous system via the trigeminal ganglion (TG). Transsynaptic virus experiments revealed that TG is connected to the hippocampus (HPC) through the corticotropin-releasing hormone (CRH) neurons of paraventricular hypothalamic nucleus (PVN) and the dopamine transporter (DAT) neurons of substantia nigra pars compacta/ventral tegmental area (SNc/VTA). Mechanistically, the data showed that TNS can increase the release of dopamine in the HPC by activating the following neural circuit: TG→CRH+ PVN→DAT+ SNc/VTA → HPC. Bulk RNA sequencing confirmed changes in the expression of dopamine-related genes in the HPC. This work preliminarily explains the efficacy and mechanism of TNS and adds to the increasing evidence demonstrating that nerve stimulation is an effective method to treat neurological diseases.
Neurotoxicity of polystyrene nanoplastics with different particle sizes at environment-related concentrations on early zebrafish embryos
2023, Science of the Total Environment
Nanoplastics (NPs) have received global attention due to their wide application and detection in various environmental or biological media. NPs can penetrate physical barriers and accumulate in organisms after being ingested, producing a variety of toxic effects and possessing particle size-dependent effects, distinguishing them from traditional contaminants. This paper explored the neurotoxicity of polystyrene (PS)-NPs of different particle sizes on zebrafish (Danio rerio) embryos at environmental concentrations at the tissue and molecular levels using visualized transgenic zebrafish. Results showed that all particle sizes of PS-NPs produced developmental toxicity in zebrafish embryos and induced neuronal loss, axonal deletion/shortening/hybridization, and developmental and apoptotic-related genetic alterations, ultimately leading to behavioral abnormalities. PS-NPs with smaller sizes may have more severe neurotoxicity due to their entry into the embryo and brain through the chorionic pore before hatching. In addition, PS-NPs at 100 nm and 1000 nm can specifically interfere with GABAergic, cholinergic or serotonergic system and affect neuronal signaling. Our results reveal the neurotoxic risk of NPs, and smaller particle-size NPs may have a greater ecological risk. We anticipate that our study can provide a basis for exploring the toxicity mechanisms of NPs and the environmental risk assessment of NPs.

View all citing articles on Scopus

View full text

Activation of c-fos in the brain

Abstract

Neuroscience

Neuroscience

Neurosci. Lett.

Neurosci. Lett.

Brain Res. Bull.

Brain Res.

Expl Neurol.

Brain Res.

Neuroscience

Neuroscience

Neuroscience

Brain Res. Mot. Brain Res.

Brain Res.

Brain Res. Mot. Brain Res.

Brain Res.

Brain Res.

Eur. J. Pharmacol: Mol. Pharmacol. Sect.

Biochem. Biophys. Res. Commun.

Brain Res.

Brain Res.

Eur. J. Pharmacol.

Brain Res. Mol. Brain Res.

Neurosci. Lett.

Neurosci. Lett.

Brain Res. Mot. Brain Res.

Neurosci. Lett.

Brain Res. Mol. Brain Res.

Mol. Brain Res.

Eur. J. Pharmacol.

Expl Neurol.

Neurosci. Lett.

Expl Neurol.

Brain Res.

Neurosci. Lett.

Expl Neurol.

Neuroscience

Brain Res.

Brain Res.

Brain Res. Mol. Brain Res.

Brain Res. Mol. Brain Res.

J. Neurosci. Meth.

Neurosci. Lett.

Neurosci. Lett.

Brain Res.

Brain Res.

Brain Res. Mol. Brain Res.

Brain Res.

Expl Neurol.

Neurosci. Lett.

Brain Res.